BIOATLA, INC. Derivative Asset, Fair Value, Gross Asset
BIOATLA, INC. (BCAB) had Derivative Asset, Fair Value, Gross Asset of $0 as of 2023-12-31, per its 10-K filed 2024-03-26.
Discontinued › Notes › Derivative Asset, Subject to Master Netting Arrangement, before Offset of Collateral
us-gaap:DerivativeFairValueOfDerivativeAsset · last filed 2024-03-26
- 2023-12-31: Derivative Asset, Fair Value, Gross Asset $0.00.
- 2023-06-30: Derivative Asset, Fair Value, Gross Asset $0.00.
- 2023-03-31: Derivative Asset, Fair Value, Gross Asset $0.00.
- 2022-12-31: Derivative Asset, Fair Value, Gross Asset $0.00.
| Period end | Derivative Asset, Fair Value, Gross Asset |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-26 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-01 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-26 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-04 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-12 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |